Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Videos|March 16, 2022
Dr. Humphrey discusses takeaways from NY GU 2022 in RCC/bladder cancer
Author(s)Urology Times staff
Advertisement
In this video, Peter A. Humphrey, MD, PhD, provides an overview of some important takeaways in bladder and kidney cancer that were discussed at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Humphrey is a professor of pathology and the director of genitourinary pathology at the Yale University School of Medicine in New Haven, Connecticut.
Advertisement
Related to this article
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5